CRISPR Therapeutics AG
$56.56
-$0.77 (-1.33%)
$55.63Day Range$59.34
Key Statistics
Market Cap
$5.54B
Shares Outstanding
96.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 19, 2016
Round Lot
100
Locale
US
Trading Data
Day Open
$58.00
Day High
$59.34
Day Low
$55.63
Volume
3.38M
VWAP
$56.59
Prev Close
$57.33
Transactions
--
Acc. Volume
--
About CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836393 employeesBAARERSTRASSE 14, ZUG(617) 315-4600IPO Oct 19, 2016US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001674416
- Ticker Root
- CRSP
- SIC Code
- 2836
About CRISPR Therapeutics AG (CRSP) Stock
CRISPR Therapeutics AG (CRSP) closed the 2026-09-18 session at $56.56, down 1.33% versus the previous close (-0.77). The stock opened at $58.00 and traded between $55.63 and $59.34 during that session. Session trading volume was 3.4M shares. The volume-weighted average price (VWAP) is $56.59.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
CRISPR Therapeutics AG has a market capitalization of $5.54 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. CRSP is listed on the XNAS exchange. The company employs approximately 393 people. The recorded listing date is 2016-10-19.
On this page you can find market CRSP stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.